Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2007

Conditions
PainCancer
Interventions
DRUG

OraVescent fentanyl (OVF)

Trial Locations (26)

10016

NYU Pain Management Center, New York

10021

Research Across America, New York

18103

Lehigh Valley Hospital, Allentown

19104

University of Pennsylvania, Philadelphia

27858

Brody School of Medicine, Greenville

29403

Charleston Hematology Oncology, PA, Charleston

30060

Center for Prospective Outcome, Marietta

32503

Gulf Coast Pain Specialists, Pensacola

33143

Lovelace Scientific Resources, Miami

34952

Hematology Oncology Associates of Treasure Coast, Port Saint Lucie

35058

Cullman Oncology and Hematology, Cullman

44718

Gabrail Cancer Center, Canton

50265

Iowa Pain Management Clinic, PC, Des Moines

59405

Donald Berdeaux, Great Falls

Great Falls Clinic, LLP, Great Falls

78229

University of Rochester, San Antonio

84015

Cache Valley Cancer Treatment and Research Clinic, Inc., West Point

84106

Lifetree Clinical Research, Salt Lake City

89106

Southern Nevada Cancer Research, Las Vegas

90404

Pacific Clinical Research, Santa Monica

90640

Clinical Trials & Research Associates, Inc., Montebello

92103

San Diego Hospice & Palliative Care, San Diego

92708

Compassionate Cancer Center, Fountain Valley

92801

Advanced Clinical Research Institute, Anaheim

Pacific Cancer Medical Center, Anaheim

92882

Compassionate Cancer Care Medical Group, Corona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cephalon

INDUSTRY